---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003919"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:04:47.615916+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rallybio Q3 net loss $10.2M ($0.37/share); cash $187M; pipeline on track

## Summary
- Net loss $10.2M vs $7.2M in Q3 2020; R&D $5.0M flat; G&A $5.0M up from $1.6M.
- Cash and equivalents $187.0M, including $83M net from August 2021 IPO.
- Initiated FNAIT natural history study to support RLYB212 registration trial design.
- On-track to report additional Phase 1/2 RLYB211 data in Q4 2021.
- Phase 1 studies for RLYB212 and RLYB116 expected to start in Q1 2022.

## SEC filing metadata
- accession: 0000950170-21-003919
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000095017021003919/0000950170-21-003919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000095017021003919/rlyb-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003919
- JSON: https://secwatch.observer/filing/0000950170-21-003919.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.